Posted by Michael Wonder on 01 Dec 2021
U.S. FDA grants Bionomics fast track designation to BNC210 for the acute treatment of social anxiety disorder and other anxiety related disorders
1 December 2021 - Bionomics is pleased to announce that the U.S. FDA has granted fast track designation to the BNC210 development program for the acute treatment of social anxiety disorder and other anxiety-related disorders.
In November 2019, the FDA granted fast track designation to the BNC210 development program for the treatment of post-traumatic stress disorder and other trauma-related and stressor-related disorders.
BNC210 is an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of social anxiety disorder and chronic treatment of post-traumatic stress disorder.
